

SUPPLEMENTAL MATERIAL

Table S1. Distribution of demographic and clinical characteristics according to age groups in patients included vs those excluded from the study.

Variable	Patients included	Patients excluded*	P value
	Age <85 years N=5,907	Age <85 years N=749	
Female sex	2,260 (38.3)	301 (40.2)	0.2941
BMI >30 kg/m ²	1,690 (29.6)	197 (28.3)	0.4781
Systemic hypertension	4,267 (72.6)	531 (71.8)	0.6211
Congestive heart failure	1,543 (28.2)	140 (23.0)	0.0072
Prior TIA/stroke/ thromboembolism	857 (14.7)	75 (10.2)	0.0009
Vascular disease	1,204 (22.0)	146 (24.1)	0.2442
Chronic renal failure	722 (12.5)	69 (9.5)	0.0190
Left atrial dilatation (diameter >40 mm)	3,443 (70.3)	441 (65.0)	0.0043
Chronic obstructive pulmonary disease	653 (11.2)	81 (11.0)	0.8622
Antithrombotic therapies			
No therapy	349 (5.9)	62 (8.3)	0.0111
Oral anticoagulant	4,917 (83.2)	608 (81.2)	0.1562
VKA	4556 (77.3)	555 (74.1)	0.0643
NOAC	361 (6.1)	53 (7.1)	0.3031
Antiplatelet only	641 (10.9)	79 (10.6)	0.8007
Oral anticoagulant plus antiplatelet	662 (11.2)	73 (9.8)	0.2295
CHA ₂ DS ₂ -VASc score	3.30±1.73	3.17±1.78	0.1156
Variable	Patients included	Patients excluded*	P Value
	Age ≥85 years N=505	Age ≥85 years N=64	
Female sex	286 (56.6)	39 (60.9)	0.5122
BMI >30 kg/m ²	59 (12.2)	8 (13.6)	0.7672
Systemic hypertension	391 (78.5)	50 (79.4)	0.8767
Congestive heart failure	210 (44.7)	22 (42.3)	0.7438
Prior TIA/stroke/ thromboembolism	104 (20.9)	7 (11.1)	0.0666
Vascular disease	138 (29.5)	14 (26.9)	0.6997
Chronic renal failure	120 (24.3)	15 (24.2)	0.9865
Left atrial dilatation (diameter >40 mm)	316 (77.3)	33 (64.7)	0.0482
Chronic obstructive pulmonary disease	74 (14.8)	7 (11.1)	0.4284
Antithrombotic therapies			
No therapy	35 (6.9)	3 (4.7)	0.4983
Oral anticoagulant	393 (77.8)	49 (76.6)	0.8197
VKA	362 (71.7)	47 (73.4)	0.7687
NOAC	31 (6.1)	2 (3.1)	0.3312
Antiplatelet only	77 (15.3)	12 (18.8)	0.4674
Oral anticoagulant plus antiplatelet	50 (9.9)	4 (6.3)	0.3478
CHA ₂ DS ₂ -VASc score	4.72±1.42	4.56±1.16	0.6112

Values are given as n. (%).

BMI= Body mass index; NOAC=Non-vitamin K antagonist oral anticoagulant; TIA=Transient ischemic attack; VKA=Vitamin K antagonist.

* Out of the 816 excluded patients, 3 patients are not reported in the Table because age was missing.

Figure S1. Net clinical benefit, adjusted for the mortality risk, of OAC vs no OAC (antiplatelet therapy only or no antithrombotic drug) according to different age strata, including ischemic stroke, systemic embolism, hemorrhagic stroke and major bleeding (without myocardial infarction) as outcome measures. OAC=Oral anticoagulant therapy.

